AZD8330 First Time in Man in Patients With Advanced Malignancies

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Cancer

Treatments: Drug: AZD8330

Study type: Interventional

Funder types: Industry

Identifiers

NCT00454090

D1536C00001

Details and patient eligibility

About

The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cancer which is refractory to standard therapies, or no therapies exist;

Exclusion criteria

• Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
• Hasn't participated in investigation drug study within 30 days;
• Brain metastases/spinal cord compression unless treated and stable,
• Off steroids/anticonvulsants.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)